Summary The taxanes are a promising family of anti-tumour drugs that block cell cycle replication by interfering with the microtubule network. The clinical use of these drugs involves some problems related to their low solubility and occurrence of resistance, which is mainly dependent on the multidrug-resistant (MDR) phenotype. To investigate the possible interaction between docetaxel and tamoxifen (TAM), three oestrogen receptor-negative cancer cell lines, MDR-MDA-MB 231, MDR + CEM-VBLr and MCF-7 ADRr, were used. In all three cell lines, the combination of docetaxel and TAM was more effective in terms of growth inhibition than single drug exposure. Isobolic analysis confirmed the presence of synergism in all cell lines when docetaxel was used at 0.2 gM and TAM at a dose equal to or higher than 1 gM. Flow cytometric DNA analysis performed on the three cell lines showed that TAM was able to increase the G/M blocking activity of docetaxel. This blocking activity was followed by an increased flow cytometric DNA fragmentation suggestive of the presence of apoptosis, which was confirmed by DNA gel fragmentation and morphological analysis. While an antagonistic effect on P-glycoprotein (P-gp) activity may contribute to the synergistic effect of tamoxifen and docetaxel on CEM-VBLr and MCF-7 ADRr, other mechanisms must be involved, as the synergistic effect is also apparent with a P-gp-negative cell line.
The taxanes are a new class of cytotoxic agents the cellular target of which is the microtubule network. Their mechanism of action is considered to be the enhancement of tubuline polymerization in both the initiation and elongation of microtubules (Schiff et al, 1979) . In this way, taxanes induce extensive formation of microtubule bundles, thereby blocking cell replication at a checkpoint between G2 and M phase of the cell cycle. Paclitaxel (formerly called taxol) and docetaxel (formerly called taxotere) were the first members of the taxane family to be developed and have been approved by the US Food and Drug Administration for the treatment of ovarian and breast cancer respectively. Phase II trials are now in progress to extend their application to a wide variety of carcinomas, including lung, colon, head and neck, prostate, cervical and brain cancer (Mastropaolo et al, 1995) . However, despite this encouraging therapeutic potential, the clinical use of these drugs involved some problems related to the solubility, toxicity and development of drug resistance, the last-named mainly dependent on an increased MDR activity (Bhalla et al, 1994) . In an attempt to minimize these problems, two complementary strategies can be employed: paclitaxel and docetaxel analogues with a better therapeutic efficacy and less toxicity can be developed and possible synergism with other chemotherapeutics can be investigated.
The aim of this study was to test the in vitro efficacy of docetaxel in association with the anti-oestrogen tamoxifen (TAM).
This combination was chosen on the basis of previous reports indicating that TAM can mediate a synergistic effect with cisplatin (McClay et al, 1989; Scambia et al, 1992) , doxorubicin (Leonessa et al, 1994) and vinblastine (Trump et al, 1992) in oestrogen receptor (ER)-negative cell lines. Our results showed that this synergism occurred in the ER-negative MCF-7 ADRr, CEMVBLr and MDA-MB 231 cell lines, since a consistent increase in docetaxel activity was found in association with TAM, thereby suggesting a possible new approach for improving the therapeutic validity of the taxane family of anti-tumour drugs.
MATERIALS AND METHODS Drugs
Docetaxel and paclitaxel were solubilized in dimethyl sulphoxide (DMSO; stock solution 10 mM) and used within 7 days. Similarly, newly developed paclitaxel analogues, IDN5102 and IDN5106, kindly provided by Indena (Milan, Italy) were prepared and used. The control cells were treated with the same amount of vehicle alone. TAM stock solutions (100 gIM) were in absolute DMSO and were used at concentrations ranging from 0.1 to 10 JIM. The final DMSO concentration never exceeded 0.2% (v/v) The CEM-VBLr cell line was grown in RPMI-1640 medium supplemented with 10% FCS, 200 U ml' penicillin and 100 ng ml' vinblastine (VBL). Cells were seeded at 2-3 x 105 cells per ml and split in a ratio of 1:3 every day. All cultures were incubated at 37°C under 5% carbon dioxide: 95% air in a high-humidity atmosphere. The MCF-7 ADRr and CEM-VBLr cell lines exhibit the classical MDR phenotype [mdr-1 mRNA and P-glycoprotein (P-gp) overexpression] and are ER negative (Berman et al, 1991; Scambia et al, 1991 
Evaluation of drug interaction
In synergy experiments, dose-response curves for the single agents were generated first. The effect of the combined treatment was analysed by the isobole method (Berenbaum, 1981) (Berenbaum, 1981 Cells were plated in the specific medium supplemented as above. After 24 h, the medium was replaced with fresh medium containing the compounds to be tested or vehicle alone. After various times of culture (from 6 h to 72 h), cells were harvested and nuclei isolated and stained using a solution containing 0.1% (m/v) sodium citrate, 0.1% (v/v) NP40, 4 mM EDTA and 50 gg ml-' propidium iodide (PI) as DNA dye . Incubation of the cells with the staining solution lasted for a minimum of 24 h at 4'C. Flow cytometric DNA ploidy analysis was performed by acquiring a minimum of 20 000 nuclei with an Epics-XL flow cytometer (Coulter Immunology, Miami, FL, USA). DNA fluorescence was collected in linear mode and pulse signal processing was used to set a doublet discrimination gate. Cell cycle analysis was performed using the Multicyle software package (Phoenix, San Diego, CA, USA).
Gel analysis of DNA fragmentation Briefly, 2.5 x 106 cells were lysed with 2 ml of lysis buffer [50 mm Tris-HCl, pH 8, 100 mM EDTA, 0.5% sodium dodecyl sulphate (SDS)] and incubated for 2 h at 56°C with 20 ,ug ml-' proteinase K (Sigma). Since the apoptotic process is responsible for the detachment of dead cells, in the MCF-7 ADRr cell line adherent and detached cells were used separately. DNA was extracted with phenol, precipitated with ethanol, resuspended in 100 ,ul of TE (10 mm Tris-HCl, pH 8, 1 mM EDTA) and incubated for 15 min at 65°C with 20 ,ugml-' RNAase A (Sigma). Aliquots (20 ml) of each sample were electrophoresed on 2% agarose gel for 1 h at 7 V cm-' and visualized with ethidium bromide staining.
Morphological analysis
Treated and control cells were seeded in eight sterile chamber slides (Nunc, Naperville, IL, USA) coated with 0.01% (v/v) poly-L-lysine (Sigma). Poly-L-lysine was used as cell adhesive to minimize the release of dead cells from the monolayer of vital adherent cells. After 24 h of culture, chambers were removed and slides were stained with May-Grunwald -Giemsa. (Bhalla et al, 1994 (IC30), which is the lowest concentration required to achieve synergism. Cell count analysis showed that an appreciable increase in cytotoxic effect was visible in all the cultures treated with the combination of docetaxel and TAM (Figure 1) . To evaluate the presence of synergism, growth experiments were analysed by the isobole method (Berenbaum, 1981) , which demonstrated a synergistic antiproliferative effect (D<l; Figure 2A and Table 2 ); under these same culture conditions, after 48 h (data not shown) and 72 h ( Figure 2B and Table 2 ), the cell cycle block disappeared and gave way to an increase in apoptosis rate, as inferred by measuring the percentage of cells in the hypodiploid region (Darzynkiewicz et al, 1992) . The same experiment was also conducted on the P-gp-negative MDA-MB 231 cell line, in which docetaxel was used at 0.1, 0.25 and 0.5 nm and TAM at 0.1, 1 and 5 JIM. Cell cycle analysis performed after 12 h (Figure 3 and Table 3 ) and 24 h (not shown) confirmed the presence of a cell cycle block in G2/M phase of the cell cycle, which subsided later with the appearance of a consistent peak of DNA fragmentation.
RESULTS
The cell cycle blocking activity was also investigated in the CEM-VBLr cell line, using docetaxel, paclitaxel and two of its Figure 4A ). The disregulation of the cell cycle was much more evident after 24 h of culture ( Figure 4B ) when, along with a more consistent G2/M block, DNA fragmentation increased, further confirming that apoptosis and cell cycle arrest were strictly and temporally correlated.
Morphological and biochemical features of apoptosis induced by docetaxel and TAM in CEM-VBLr and MCF-7 ADRr cells
In many cell systems, low molecular weight DNA fragments produced during apoptotic endonucleolysis are responsible for the typical 'ladder' pattern in agarose gel electrophoresis (Wyllie, 1980) . To confirm further that the combination of docetaxel and TAM actually induced apoptosis, DNA fragmentation gel electrophoresis was performed in the CEM-VBLr and MCF-7 ADRr cell lines. A typical 'ladder' pattern was found when the combination was tested on CEM-VBLr cells, whereas no signs of DNA 'laddering' were evident in the MCF-7 ADRr cell line ( Figure 5 ). This suggests that apoptosis may also occur in the absence of the classical low molecular weight DNA fragmentation. In order to test this hypothesis, classical nuclear changes related to the apoptotic process -reduction of nuclear size, chromatin condensation, marginalization and nuclei fragmentation were investigated by morphological analysis (Figure 6 ). MCF-7 ADRr cells were treated with docetaxel alone and with increasing doses of TAM (0.1, 1 and 10 tM). Jordan and Murphy, 1990) . Moreover, it has been reported previously that TAM may induce ER-independent apoptosis in human breast cancer cells (Perry et al, 1995) . MCF-7 ADRr and CEM-VBLr are cell lines characterized by the classical MDR phenotype with overexpression of P-gp activity. TAM was previously reported to be an MDR phenotype reverting agent (Ramu et al, 1984) , and the taxanes are known to be a substrate of P-gp activity. So, on principle, the synergistic effect observed here could be dependent on modulation of P-gp activity. However, TAM was previously probed in vitro and in vivo (Hofmann et al, 1988; McClay et al, 1989; Scambia et al, 1992) as a synergistic agent for cisplatin, which induces a P-gp-independent resistance. Furthermore, our previous reports showed that, in contrast to other antioestrogens, such as ICI 182, 780, TAM was unable under our culture conditions to revert the MDR phenotype classically in terms of modulation of P-gp protein, MDR-1 mRNA expression or efflux activity as measured by rhodamine 123-based assay (De Vincenzo et al, 1996) . Moreover, the combination of docetaxel and TAM was also effective on MDA-MB 231, indicating -that the synergism also operates in cell lines that do not express P-gp activity. B D Figure 6 Morphological analysis of MCF-7 ADRr cells cultured in the presence of vehicle alone (0.2% DMSO; A) 0.2 gM docetaxel alone (B), 0.2 gM docetaxel and 1 gM TAM (C) and 0.2 gM docetaxel plus 10 gM TAM (D). Cells were grown in eight-chamber slides and cultures were interrupted after 24 h and stained with May-Grunwald-Giemsa. In (A), cells are characterized by a finely granular chromatin texture and several nucleoli. In (B), chromatin texture is similar to (A), but an increased amount of anisonucleosis is detectable. In (C), there is a consistent decrease in the number of nucleoli and some cells show nuclear shrinkage and polarization and/or chromatin condensation into crescents along the nuclear envelope (arrows). In (D), in virtually all the cells nucleoli are absent and a large number of cells show condensed and highly fragmented chromatin and/or apoptotic bodies in the cytoplasm (arrows)
Cell cycle analysis showed that the synergism was associated with an increased number of cells blocked in G2/M phase of the cell cycle, indicating that the presence of high levels of TAM induces cell cycle arrest at concentrations of docetaxel that are ineffective if used alone. Interestingly, after cell cycle block in the G2/M phase of the cell cycle, an augmentation of flow cytometric DNA fragmentation -a hallmark of apoptosis in a number of experimental models (Darzynkiewicz et al, 1992) analysis in MCF-7 ADRr cells. In keeping with previous reports (Bardon et al, 1987; Warn et al, 1993) , in this cell system typical apoptotic nuclear morphology was found in the absence of the classical low molecular weight DNA fragmentation, thereby confirming that 'ladder' pattern DNA is not a mandatory endpoint of the apoptotic process.
An increased blocking activity and induction of flow cytometric DNA fragmentation was also noticed for paclitaxel and its two newly developed analogues, prompting us to hypothesize that all the members of the taxane family share with docetaxel the ability to interact positively with TAM. Taken together, these findings indicate that the increased G2/M blocking activity culminates in the massive induction of apoptosis and suggest that the chemosensitizing effect of TAM may reflect its ability to facilitate a docetaxel-induced apoptosis. Some pharmacological properties of TAM could be responsible for this phenomenon, such as calcium channel blocking activity (Lopes et al, 1990) , inhibition of protein kinase C (Issandou et al, 1990 ) and production of reactive oxygen species with consequent downward expression of intracellular thiols (C Ferlini, unpublished results). Further studies on these possible mechanisms of action are now in progress in our laboratory to clarify whether they are targeted during apoptosis induced by the combination of docetaxel and TAM.
The minimum doses required to obtain synergism in both MDRpositive cell lines were 1 ,UM TAM and 0.2 gM docetaxel, and these are clinically important because similar levels can safely be achieved (Sclichenmyer and Von Hoff, 1991; Trump et al, 1992) , particularly inside the tumour tissue, where TAM levels may considerably exceed those in the peripheral circulation (Lien et al, 1991) . The taxanes are currently used in polychemotherapy protocols, and there may be obvious theoretical advantages in adding TAM to taxane-containing regimens, since it acts as a synergistic agent in combination with other important anti-tumour drugs, such as doxorubicin and cisplatin. Thus, if these results are confirmed using in vivo models, prospective clinical trials will be essential to verify whether the addition of TAM to taxane-containing regimens is clinically relevant.
